Multiple myeloma treatments are entering a pivotal phase, with a new market analysis from The Business Research Company projecting explosive growth in B-cell maturation antigen (BCMA) targeted therapies over the next several years. The report offers a detailed roadmap of where the sector stands today and where it is heading.
The Business Research Company’s B-Cell Maturation Antigen (BCMA) Targeted Therapies Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035
The field of targeted cancer treatments is shifting rapidly, particularly for therapies designed to combat multiple myeloma. B-cell maturation antigen (BCMA) targeted therapies have emerged as a major focus because of their encouraging clinical results and novel mechanisms of action. This analysis breaks down the current market forces, primary growth drivers, dominant regions, and the projected trajectory for the BCMA targeted therapies market.
Also worth a look: Automated cell culture equipment market heads to $4.03B by 2030 as personalized medicine accelerates demand and Behavioral therapy market surges to $240B as mental health demand climbs.
Market climbing steadily with double-digit annual gains
The BCMA targeted therapies market has seen notable momentum in recent years. According to the report, it is set to climb from $15.09 billion in 2025 to $18.75 billion in 2026, reflecting a compound annual growth rate (CAGR) of 24.3%. That surge during the historical period is tied to deeper knowledge of BCMA biology, rising multiple myeloma diagnoses, early wins in clinical trials for BCMA-directed drugs, growth in hematology oncology centers, and greater funding for immuno-oncology research.
Download a free sample of the b-cell maturation antigen (bcma) targeted therapies market report:
https://thebusinessresearchcompany.com/sample_request?id=96041040&type=smp&name=B-Cell%20Maturation%20Antigen%20%28BCMA%29%20Targeted%20Therapies%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR
Forecast points to $44.29 billion by 2030
Looking further out, the market is expected to expand dramatically, hitting $44.29 billion by 2030 on a robust CAGR of 24.0%. That projected growth is supported by a wave of approvals for next-generation BCMA therapies, increasing demand for off-the-shelf immunotherapies, wider use of combination treatment plans, a push for lasting remission, and growing reliance on AI-driven patient stratification. Key developments shaping the market in this period include broader adoption of CAR-T cell therapies, progress in bispecific antibody platforms, greater use of BCMA-targeted antibody-drug conjugates (ADCs), advances in personalized immunotherapy protocols, and a sharper focus on treating relapsed and refractory multiple myeloma cases.
How BCMA therapies work and why they matter
BCMA targeted therapies are a set of treatment strategies engineered to attach specifically to BCMA, a protein present on the surface of mature B-cells and plasma cells. BCMA is part of the tumor necrosis factor (TNF) receptor superfamily and is central to the development, survival, and differentiation of B-cells into plasma cells. These therapies represent a major advance in managing multiple myeloma, giving patients with relapsed or refractory disease access to more precise and effective treatment options.
View the full b-cell maturation antigen (bcma) targeted therapies market report:
https://thebusinessresearchcompany.com/report/b-cell-maturation-antigen-bcma-targeted-therapies-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR
Rising multiple myeloma cases fuel demand
The growing number of multiple myeloma cases is a key factor pushing the BCMA targeted therapies market forward. Multiple myeloma is a cancer of plasma cells, which are essential to the immune system’s antibody production. The uptick in cases stems from an aging global population, better diagnostic tools, and uneven healthcare access. BCMA targeted therapies work by homing in on and eliminating malignant plasma cells that express BCMA, offering a path to more precise and effective treatment. For example, in August 2024, the American Cancer Society said roughly 35,780 new multiple myeloma cases were diagnosed in the United States during 2024, including 19,520 in men and 16,260 in women. About 12,540 deaths are projected, with 7,020 among men and 5,520 among women. That rising disease burden is a major driver of market growth.
North America leads, but the map is global
In 2025, North America held the largest share of the BCMA targeted therapies market. The report’s geographic coverage spans Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a broad view of the market’s worldwide reach and growth potential.
Our 2026 market reports now include enhanced strategic insights through:
• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info
The Business Research Company – www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company
Oliver Guirdham
The Business Research Company
+44 7882 955267
Visit us on social media:
LinkedIn
Facebook
X
Why it matters: The projected near-tripling of the BCMA targeted therapies market underscores a broader shift toward precision medicine in oncology, where treatments are increasingly tailored to specific biological targets. For patients, investors, and healthcare providers, this growth signals both expanding treatment options and a competitive landscape that could reshape how multiple myeloma is managed for years to come.
